Is There a Vaccine for Herpes Simplex Virus (HSV)?

No vaccine against herpes simplex virus is currently approved or available anywhere in the world, despite decades of effort and the fact that HSV is one of the most common infections on the planet. An estimated 3.7 billion people under 50 carry HSV-1, and roughly 490 million carry HSV-2, together making herpes one of the most widespread viral infections in humans.¹ The gap between that burden and the absence of a vaccine reflects the virus’s unusual biology, a history of high-profile clinical trial failures, and, more recently, a wave of preclinical candidates that may finally be gaining traction.

Why HSV Has Been Uniquely Difficult to Vaccinate Against

Most successful vaccines work by training the immune system to recognize a pathogen before it takes hold. HSV subverts that strategy by establishing a lifelong hidden infection inside nerve cells. After an initial bout of replication on skin or mucosal surfaces, the virus travels along nerve fibers and parks its DNA in the nuclei of sensory neurons, entering a quiet state called latency. From that refuge, it can periodically reactivate, traveling back to the surface to produce new infectious virus or cause sores.² During latency, the virus produces almost no proteins for the immune system to detect. No infectious virus is circulating, and the genome sits largely silent inside a cell type the immune system handles gently to avoid damaging the nervous system.³

On top of its hiding strategy, HSV actively sabotages the immune response even when it is replicating. The virus carries a toolkit of proteins that interfere with the signaling pathways cells use to sound the alarm against invaders. Multiple viral proteins directly target the molecular machinery that produces interferons and other early warning signals, dampening the host’s innate immune response before it can fully engage.⁴ This combination of stealth and active countermeasures means that even people who mount a strong natural immune response after infection are not fully protected against reactivation or reinfection. A vaccine has to do better than natural immunity, and that is a high bar.

Why Earlier Vaccine Trials Failed

The most prominent attempt at an HSV vaccine focused on a single viral surface protein called glycoprotein D (gD). In large clinical trials, the gD-based vaccine produced robust neutralizing antibodies but still failed to prevent HSV-2 infection. Researchers traced part of the problem to the type of immune response the vaccine triggered. It generated antibodies that could block the virus from entering cells in a lab dish but did not produce antibodies capable of flagging infected cells for destruction by immune cells, a process called antibody-dependent cell-mediated cytotoxicity, or ADCC. In studies of women who received the vaccine, the antibody response mirrored this limitation: strong neutralization, but no meaningful ADCC activity.⁵

The durability of gD vaccine responses was also disappointing. In mice, antibodies from a gD protein vaccine declined substantially within six months, and protection against challenge disappeared entirely after that window. A newer candidate called ΔgD-2, engineered to present a virus missing gD entirely, triggered both neutralizing and ADCC antibodies that remained strong for at least a year and maintained protection at every time point tested.⁶ The takeaway from this line of research has reshaped how vaccine designers think about HSV: neutralization alone is not enough. A successful vaccine probably needs to provoke a broader, multifunctional antibody response along with strong T-cell immunity.

The mRNA Vaccine Approach

The technology behind COVID-19 vaccines has opened a new chapter for HSV vaccine development. Several groups are now testing mRNA-based candidates that encode HSV surface proteins, delivered in lipid nanoparticles. One line of work focuses on glycoprotein C (gC2), a protein HSV-2 uses to block the complement system, which is one of the body’s earliest antimicrobial defenses. In mice, mRNA encoding gC2 was highly protective even at the lowest dose tested. The antibodies it generated did not just neutralize the virus; they specifically blocked the virus’s ability to shut down complement activation, and those complement-restoring antibodies turned out to be the ones driving protection.⁷

Other teams are combining multiple glycoproteins into a single mRNA vaccine. One study tested monovalent (gD2 alone) and bivalent (gD2 paired with either gC1 or gE1) candidates in mice. All three generated strong antibody and T-cell responses and protected against vaginal HSV challenge, but the gD2-gE1 combination produced markedly stronger immune responses than gD alone.⁸ The logic behind multi-antigen strategies is that targeting several viral proteins at once makes it harder for the virus to slip past the immune response. That thinking echoes what the gD-only trial failures revealed: hitting the virus from a single angle is not enough.

Computational approaches are also being used to design multi-epitope mRNA vaccines from scratch, using reverse vaccinology to identify the most promising immune targets across the HSV-2 proteome.⁹ These are still at the design and simulation stage, but they reflect a broader effort to move beyond the single-protein vaccines that defined earlier generations of HSV research.

Therapeutic Vaccines for People Already Infected

Most HSV vaccine work aims to prevent infection in the first place. But a separate category of candidates targets people who already carry the virus, with the goal of reducing outbreaks and viral shedding rather than clearing infection entirely. The most clinically advanced therapeutic vaccine to date was GEN-003, a protein-based vaccine tested in multiple randomized trials in people with genital HSV-2.

In one trial, GEN-003 at the lower dose cut genital viral shedding by roughly half immediately after vaccination, and the reduction persisted at six months, though it faded back toward baseline by twelve months.¹⁰ A follow-up dose-ranging trial tested several combinations of antigen and adjuvant amounts. At the highest doses, shedding reductions were durable for twelve months, and lesion rates dropped as well.¹¹ A further trial confirmed that the optimized dose reduced shedding by about 40% and also cut lesion rates and the duration of recurrences.¹²

GEN-003 never advanced to a Phase 3 trial; its developer ran into financial trouble and the program stalled. But the data remain important because they showed that a vaccine could meaningfully reduce shedding and recurrences in humans who already have genital herpes. That proof of concept continues to inform new therapeutic candidates.

Getting Immunity to the Right Place

One persistent challenge is that standard intramuscular vaccination generates systemic immunity, circulating antibodies and T cells in the blood, but HSV attacks mucosal surfaces where those circulating defenses may not arrive fast enough. A growing body of research emphasizes the importance of tissue-resident memory T cells, immune cells that park themselves in mucosal tissue and respond immediately to local reinfection without needing to be summoned from the bloodstream.¹³

A strategy called “prime and pull” tries to solve this delivery problem. The idea is to prime the immune system with a conventional injection, then pull the activated T cells into the genital tract using a chemical signal applied topically. In mice, this approach established long-lived T cells in vaginal tissue that blocked HSV-2 from reaching the nervous system and prevented clinical disease.¹⁴ A simpler variation replaced the chemokine with a topical application of the inexpensive antibiotic neomycin, which triggered a local inflammatory signal that recruited T cells to vaginal tissue just as effectively.¹⁵

More recently, researchers tested a two-step regimen combining intramuscular mRNA priming with a vaginal boost using recombinant protein and a novel nanoparticle adjuvant. The vaginal boost increased local resident T-cell populations and mucosal antibodies, and protection required both local antigen and local adjuvant delivery together.¹⁶ These approaches are still entirely preclinical, but they reflect an important conceptual shift: the route of vaccination may matter as much as the vaccine itself.

Gene Editing Instead of Vaccination

A fundamentally different strategy bypasses vaccination altogether and aims to destroy the latent virus directly inside nerve cells. Using gene-editing enzymes delivered by harmless viral vectors (adeno-associated viruses, or AAVs), researchers have shown they can cut HSV DNA where it hides. In an early proof of concept, AAV-delivered meganucleases eliminated over 90% of latent HSV from the nerve ganglia of mice.¹⁷ Later work refined the approach, using a combination of different AAV types to deliver two meganucleases simultaneously. That regimen eliminated up to 97% of latent HSV DNA in a mouse model of genital infection, and treated animals showed reduced viral shedding.¹⁸

A parallel effort using CRISPR-Cas9, the more widely known gene-editing system, showed promise in a rabbit model of HSV-1 eye disease. A single AAV dose delivering the CRISPR machinery reduced viral DNA and RNA in the nerve tissue and inhibited viral reactivation.¹⁹ The earlier mouse work found that meganucleases outperformed CRISPR/Cas9 for this particular task, though the field is still working out which editing tool performs best in larger animals and ultimately humans.

Gene editing for HSV is genuinely exciting because it targets the reservoir that vaccines cannot reach, the latent viral DNA itself. But the gap between mouse ganglia and human ganglia is wide. Human nerve clusters are larger, the AAV vectors need to reach deep tissue reliably, and any off-target cuts in human DNA would be a serious safety concern. No human trials have begun yet.

The Animal Model Problem

A persistent frustration in HSV vaccine research is that success in animals has repeatedly failed to predict success in people. Mice are the workhorse model, but they don’t spontaneously reactivate HSV the way humans do, which limits their usefulness for testing therapeutic vaccines. Guinea pigs and rabbits develop spontaneous reactivation and recurrent disease, making them better models in some respects, but their immune systems don’t mount responses to the same molecular targets that the human immune system recognizes.²⁰

There is also the question of prior HSV-1 infection. Over half of adults already carry HSV-1, and there is evidence that HSV-1 antibodies offer some degree of cross-protection against HSV-2 acquisition.²¹ But almost all preclinical vaccine studies use HSV-1-negative animals. When one group tested the gD vaccine in guinea pigs that were already HSV-1 seropositive, the vaccine worked in the animals even though it had failed in HSV-1 seropositive women in clinical trials. The animal model simply didn’t capture the real-world immune landscape.²² This mismatch is a recurring blind spot. Future vaccine trials will need to account for the pre-existing immunity that most human recipients bring to the table.

Protecting Newborns Through Maternal Vaccination

Neonatal herpes is rare, but when it occurs it can be devastating, causing disseminated infection, brain damage, or death. One vaccine strategy sidesteps the difficulty of vaccinating a newborn’s immature immune system entirely by immunizing the mother before birth. Maternal antibodies cross the placenta and can protect the infant during the vulnerable first weeks of life.

A trivalent subunit vaccine targeting three HSV-2 glycoproteins (gC2, gD2, and gE2) protected offspring against disseminated neonatal herpes and death in a mouse model when given to mothers before mating.²³ An mRNA version of a similar vaccine produced comparable antibody levels in mothers and pups, protected both first and second litters, and was the preferred candidate over the protein version because of its stronger performance against genital herpes in the mother.²⁴ None of these are in human trials for this purpose, but the concept has a track record with other pathogens and could be one of the faster paths to clinical use if an HSV vaccine proves safe in adults.

Why an HSV Vaccine Would Matter Beyond Herpes

HSV-2 infection substantially increases the risk of acquiring HIV. The virus causes genital ulcerations and draws HIV’s preferred target cells, activated CD4 T cells and dendritic cells, into the genital mucosa, creating a biological welcome mat for HIV entry.²⁵ In high-prevalence settings like South Africa, this interaction has enormous consequences. A mathematical modeling study projected that an 80% effective prophylactic HSV-2 vaccine with 80% uptake could reduce HSV-2 incidence by about 84% and HIV incidence by roughly 65% over 40 years. Even a therapeutic vaccine, reaching only symptomatic individuals, could cut HIV incidence by about a quarter over the same period.²⁶

For HSV-1, modeling suggests that infant vaccination with 70% efficacy introduced in 2030 could avert tens of millions of cumulative infections by 2075, with the number needed to vaccinate to prevent one infection dropping from about 36 in the first decade to roughly 7 by the 2070s. Adding adolescent catch-up vaccination would amplify the effect, especially for genital HSV-1 infections, which have been rising in younger populations.²⁷ These projections are hypothetical, of course, since no vaccine with those characteristics exists yet. But they illustrate why public health agencies see HSV vaccines as a priority that extends well beyond cold sores and genital ulcers.

Where Things Stand Right Now

With no approved vaccine in sight for the immediate future, the current standard of care for HSV remains antiviral drugs like acyclovir and valacyclovir. These reduce outbreaks and lower the risk of transmission, but they don’t cure infection or fully prevent shedding. A newer antiviral, pritelivir, recently completed a Phase 3 trial and received FDA priority review for refractory HSV infections in immunocompromised patients, a population for whom existing drugs often fail.²⁸ That is an improvement in treatment, not a vaccine, but it matters for people running out of options.

On the vaccine front, the honest assessment is that the field is rich in preclinical promise and poor in clinical data. Multiple mRNA candidates, live-attenuated viruses, subunit vaccines, and gene-editing approaches show strong results in animals. DNA vaccine candidates using novel adjuvants have demonstrated both prophylactic and therapeutic activity in guinea pig models, reducing latent viral DNA in nerve tissue and cutting the frequency of recurrent disease and viral shedding.²⁹ But as the field has learned repeatedly, animal success does not guarantee human efficacy, and the translational gap for HSV has been wider than for many other viruses.

There are reasons for cautious optimism. Researchers now understand much better why earlier vaccines failed, and the newer candidates are designed specifically to avoid those mistakes: broader antigen targets, ADCC-competent antibody responses, mucosal delivery strategies, and multi-functional immune activation. The mRNA platform offers faster development timelines than traditional protein vaccines. And gene editing, while further from the clinic, represents an entirely new angle of attack that could eventually complement vaccination by going after latent virus directly. The question is less whether an HSV vaccine is theoretically possible and more whether any current candidate can survive the leap from mouse to human. The next five to ten years of clinical trials should begin to answer that.

The Stigma Question

One dimension of HSV that rarely appears in vaccine research papers but profoundly affects the people living with the virus is stigma. Genital herpes carries a social and psychological burden that is wildly disproportionate to its physical severity in most people. Many individuals experience more distress from the diagnosis itself than from the symptoms. Modeling work on hypothetical curative therapies has noted that beyond reducing transmission, the availability of a cure or a highly effective vaccine could help alleviate the stigma surrounding HSV-2 and mitigate the psychosocial harms that come with it.³⁰ That is a harder outcome to model than viral shedding rates, but for millions of people it may be the benefit that matters most.